Results 91 to 100 of about 119,169 (307)

HDAC inhibition potentiates immunotherapy in triple negative breast cancer. [PDF]

, 2017
Triple-negative breast cancer (TNBC) represents a more aggressive and difficult subtype of breast cancer where responses to chemotherapy occur, but toxicity is significant and resistance often follows. Immunotherapy has shown promising results in various
Ali, Niwa, Budillon, Alfredo, Krings, Gregor, Munster, Pamela N, Park, Jeenah, Pawlowska, Nela, Rosenblum, Michael D, Terranova-Barberio, Manuela, Thomas, Scott   +8 more
core   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Differences in checkpoint-inhibitor-induced hypophysitis: mono- versus combination therapy induced hypophysitis

Frontiers in Endocrinology
ObjectiveImmune checkpoint inhibitors (ICIs) are revolutionary in oncology but may cause immune-related (IR) side effects, such as hypophysitis. Treatment with anti-PD-(L)1, anti-CTLA-4 or anti-CLTA-4/PD-1 may induce hypophysitis, but little is known ...
Stephanie van der Leij, Stephanie van der Leij, Karijn P.M. Suijkerbuijk, Medard F.M. van den Broek, Medard F.M. van den Broek, Gerlof D. Valk, Gerlof D. Valk, Jan Willem Dankbaar, Hanneke M. van Santen, Hanneke M. van Santen   +9 more
doaj   +1 more source

CTLA-4 · FasL Induces Alloantigen-Specific Hyporesponsiveness [PDF]

The Journal of Immunology, 2003
AbstractThe APC:T cell interface can be effectively targeted with immunotherapeutic proteins. We previously described a unique trans signal converter protein, CTLA-4 · Fas ligand (FasL), that has the inherent capacities to tether the T cell inhibitor FasL (CD95 ligand) to the surfaces of B7 (CD80 and CD86)-positive APC (via CTLA-4:B7 interaction), and ...
Michal Dranitzki, Elhalel, Jui-Han, Huang, William, Schmidt, Jacob, Rachmilewitz, Mark L, Tykocinski   +4 more
openaire   +2 more sources

CD28 between tolerance and autoimmunity: The side effects of animal models [version 1; referees: 2 approved] [PDF]

, 2018
Regulation of immune responses is critical for ensuring pathogen clearance and for preventing reaction against self-antigens. Failure or breakdown of immunological tolerance results in autoimmunity.
A Aruffo, A Levine, A Paterson, A Schneider, B Salomon, C Brunstein, C Camperio, C Dendrou, C Lin, C Peterfy, D Franckaert, D Tyrsin, E Hui, E Mayer, F Lühder, G Burmester, G Freeman, G Suntharalingam, H Gmünder, H Ko, I McInnes, I Vogel, J Esensten, J Gross, J Kremer, J Vahl, K Haanstra, M Kishore, M Kunkl, M Tacke, M Vierboom, M Wagner, N Beyersdorf, N Dilek, N Ohkura, N Poirier, N Porciello, N Porciello, O Acuto, P Emery, P Linsley, P Martin, P Tabares, Q Zhang, R Westhovens, R Westhovens, R Zhang, R Zhang, R Zhang, S Bhela, S Khoury, S Weißmüller, S Yao, T Hünig, T Hünig, T Thauland, T Thaventhiran, X He   +57 more
core   +2 more sources

Decoding the Cardiac Immune Microenvironment and Fibroblast Crosstalk in Radiotherapy Combined with Immunotherapy‐Induced Cardiac Fibrosis Based on Single‐Cell Transcriptomic Analysis

Advanced Science, EarlyView.
This study highlights that radioimmunotherapy drives crosstalk between fibroblasts and immune cells (especially macrophages) in the cardiac microenvironment, with IL‐6 as the key mediator, and tocilizumab alleviates cardiac fibrosis by targeting this interplay.
Yuxi Luo, Ying Yu, Zhimin Zeng, Yanxin Chen, Yali Yi, Zhiqin Lu, Fujuan Zeng, Peng Xu, Daya Luo, Leifeng Chen, Anwen Liu   +10 more
wiley   +1 more source

Therapeutic use of anti-CTLA-4 antibodies [PDF]

International Immunology, 2014
Abstract Targeting CTLA-4 represents a new type of immunotherapeutic approach, namely immune checkpoint inhibition. Blockade of CTLA-4 by ipilimumab was the first strategy to achieve a significant clinical benefit for late-stage melanoma patients in two phase 3 trials.
Christian U, Blank, Alexander, Enk
openaire   +2 more sources

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]

, 2015
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core   +2 more sources

Macrophage Extracellular Traps in Immunity and Cancer

Advanced Science, EarlyView.
As a macrophage‐mediated innate defense mechanism, the dysregulated release of METs drives chronic inflammation and influences tumor progression. Furthermore, METs exhibit a functional duality within the tumor microenvironment, capable of both promoting and suppressing tumor development.
Junyao Li, Eugenie Nepovimova, Adam Grundel, Lukas Peter, Qinghua Wu, Kamil Kuca   +5 more
wiley   +1 more source

Unraveling the role of Ctla-4 in intestinal immune homeostasis through a novel Zebrafish model of inflammatory bowel disease

eLife
Inflammatory bowel disease (IBD) is a chronic and relapsing immune-mediated disorder characterized by intestinal inflammation and epithelial injury. The underlying causes of IBD are not fully understood, but genetic factors have been implicated in genome-
Lulu Qin, Chongbin Hu, Qiong Zhao, Yong Wang, Dongdong Fan, Aifu Lin, Lixin Xiang, Ye Chen, Jianzhong Shao   +8 more
doaj   +1 more source